文献速递肿瘤 PET/CT

抗CEA双特异性抗体预靶向免疫PET显像在结直肠癌转移中的初步临床研究

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-08-21

该初步研究评估了抗CEA重组双特异性单克隆抗体TF2与[68Ga]Ga标记的HSG肽IMP288预靶向免疫PET在转移性结直肠癌患者中的显像性能,共纳入11例患者,结果显示免疫PET安全可行,病灶分析灵敏度88%、特异度100%、阳性预测值100%、阴性预测值67%,并对2例患者的管理产生了影响。

要点

  • 预靶向免疫PET使用TF2抗体和[68Ga]Ga-IMP288肽,未见注射相关不良反应。
  • 病灶分析中免疫PET灵敏度88%、特异度100%、阳性预测值100%、阴性预测值67%。
  • 免疫PET对2例患者的管理产生了影响。

核心结论

  • 预靶向免疫PET使用抗CEA/抗IMP288双特异性抗体和[68Ga]Ga标记的半抗原安全可行,诊断性能有前景。

研究设计与样本

  • 前瞻性初步研究纳入11例需诊断转移或CEA升高监测的结直肠癌患者,均接受内镜超声、胸腹盆CT、腹部MRI和FDG-PET,免疫PET前静脉注射120 nmol TF2,30小时后静脉注射150 MBq [68Ga]Ga-IMP288。
  • 金标准为组织学和6个月随访后影像。

主要发现

  • 患者分析中免疫PET在9/11例为阳性,病灶分析中14个病灶有12个为阳性。
  • 免疫PET病灶的中位SUVmax为7.65(范围3.98-13.94,SD 3.37),MTV为8.63 cm3(范围1.98-46.64,SD 14.83),TLG为37.90 cm3(范围8.07-127.5,SD 43.47)。
  • 病灶分析中EUS/CT/MRI联合的灵敏度、特异度、阳性预测值、阴性预测值分别为82%、25%、82%、25%。
  • FDG-PET的灵敏度、特异度、阳性预测值、阴性预测值分别为76%、67%、87%、33%。
  • 免疫PET的灵敏度、特异度、阳性预测值、阴性预测值分别为88%、100%、100%、67%,并对2例患者的管理产生影响。

临床怎么用

  • 对于CEA升高或需诊断转移的结直肠癌患者,可考虑预靶向免疫PET作为补充影像手段,其初步诊断性能有前景且安全可行。

局限性

  • 本研究为初步研究,样本量仅11例,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This pilot study evaluated the imaging performance of pretargeted immunological positron emission tomography (immuno-PET) using an anti-carcinoembryonic antigen (CEA) recombinant bispecific monoclonal antibody (BsMAb), TF2 and the [68Ga]Ga-labelled HSG peptide, IMP288, in patients with metastatic colorectal carcinoma (CRC). PATIENTS AND METHODS: Patients requiring diagnostic workup of CRC metastases or in case of elevated CEA for surveillance were prospectively studied. They had to present with elevated CEA serum titre or positive CEA tumour staining by immunohistochemistry of a previous biopsy or surgical specimen. All patients underwent endoscopic ultrasound (EUS), chest-abdominal-pelvic computed tomography (CT), abdominal magnetic resonance imaging (MRI) and positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET). For immuno-PET, patients received intravenously 120 nmol of TF2 followed 30 h later by 150 MBq of [68Ga]Ga-labelled IMP288, both I.V. The gold standard was histology and imaging after 6-month follow-up. RESULTS: Eleven patients were included. No adverse effects were reported after BsMAb and peptide injections. In a per-patient analysis, immuno-PET was positive in 9/11 patients. On a per-lesion analysis, 12 of 14 lesions were positive with immuno-PET. Median SUVmax, MTV and TLG were 7.65 [3.98-13.94, SD 3.37], 8.63 cm3 [1.98-46.64; SD 14.83] and 37.90 cm3 [8.07-127.5; SD 43.47] respectively for immuno-PET lesions. Based on a per-lesion analysis, the sensitivity, specificity, positive-predictive value and negative-predictive value were, respectively, 82%, 25%, 82% and 25% for the combination of EUS/CT/MRI; 76%, 67%, 87% and 33% for FDG-PET; and 88%, 100%, 100% and 67% for immuno-PET. Immuno-PET had an impact on management in 2 patients. CONCLUSION: This pilot study showed that pretargeted immuno-PET using anti-CEA/anti-IMP288 BsMAb and a [68Ga]Ga-labelled hapten was safe and feasible, with promising diagnostic performance. TRIAL REGISTRATION: ClinicalTrials.gov NCT02587247 Registered 27 October 2015.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Touchefeu Y, Bailly C, Frampas E, et al. Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study. Eur J Nucl Med Mol Imaging. 2020. PMID: 32820369. doi:10.1007/s00259-020-04989-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。